The project was discussed on 14th June with the Director of Saint-Petersburg Institute of Phthisiopulmonology Pyotr Yablonsky.
KFU and the Institute signed a cooperation agreement in March 2018. The two sides have been working on the medication since then, as Head of KFU Pharmaceutics Center Yury Shtyrlin explained, “The substance will move to preclinical trials by the end of 2019.” This stage will take about three years, and the same period will be required for clinical trials.
Dr. Yablonsky commented, “I am impressed by the equipment and the researchers that I’ve seen here. Firstly, I really appreciate the team’s motivation – they found permanent funding and have achieved fantastic results. I am delighted that you are capable of finding financial sources despite all obstacles.”
Rector Ilshat Gafurov assured the guests of KFU’s eagerness to continue cooperation.
Source text: Kamill Gareev
Photos: Mariya Abrosimova
Translation: Yury Nurmeev